Diabetic Retinopathy Market Size & Growth Forecast 2027–2036, By Segments (Type, Management), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Diabetic Retinopathy Market size was over USD 10.7 billion in 2026 and is likely to grow at a 6.08% CAGR between 2027 and 2036, exceeding USD 19.31 billion by 2036. The industry revenue for 2027 is calculated at USD 11.25 billion.

• Base Year Value (2026): USD 10.7 billion
• CAGR (2027-2036): 6.08%
• Forecast Year Value (2036): USD 19.31 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Diabetic Retinopathy Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 40.07% of the market in 2026, supported by established screening programs, broad specialist access, structured reimbursement, and consistent demand for diagnosis, monitoring, and treatment.
  • Asia Pacific is projected to grow at a 7.35% CAGR as diabetes prevalence rises, screening expands, retinal imaging adoption increases, and more patients enter formal diagnosis and treatment pathways.

• Segment Momentum:

  • Non-proliferative Diabetic Retinopathy accounted for 67.39% of the market in 2026 because it is the earlier and more commonly diagnosed stage, supporting consistent monitoring, treatment, and ongoing care demand.
  • Laser Surgery is the fastest-growing management segment because it addresses progressing and advanced disease requiring durable procedural intervention, providing targeted retinal control when pharmacologic treatment alone is insufficient.

• Market Expansion Drivers:

  • Rising diabetes prevalence and aging population increasing risk of vision impairment cases.
  • Advanced diagnostic imaging and laser therapies improving early-stage disease treatment outcomes.
  • AI-enabled retinal screening adoption enhancing early detection in primary care settings.

• Leading Market Participants:

  Key companies in the diabetic retinopathy market include Bayer AG (Germany), AbbVie Inc. (United States), Novartis AG (Switzerland), Genentech, Inc. (United States), Alimera Sciences, Inc. (United States), Kowa Company, Ltd. (Japan), Oxurion NV (Belgium), Sirnaomics Ltd. (United States), Regeneron Pharmaceuticals, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 10.7 billion
  • 2027 Estimated Market Size: USD 11.25 billion.
  • Projected Market Size: USD 19.31 billion by 2036
  • Growth Forecasts: 6.08% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Non-proliferative Diabetic Retinopathy (Type) | Anti-VEGF (Management)
  • Emerging Opportunity Segment: Proliferative Diabetic Retinopathy (Type) | Laser Surgery (Management)

Market Growth Drivers and Industry Trends

Rising diabetes prevalence and aging population increasing risk of vision impairment cases

The growing burden of diabetes, combined with population aging, is increasing the number of individuals vulnerable to retinal vascular damage and progressive vision loss, which will drive the diabetic retinopathy market growth. Longer diabetes duration raises the likelihood of developing retinal complications, while older populations face greater exposure to age-related visual impairment and coexisting metabolic conditions. This expanding patient pool is increasing demand for routine retinal examinations, disease monitoring, ophthalmic consultations, and interventions aimed at preventing progression from early retinal abnormalities to more severe stages requiring specialized care.

Advanced diagnostic imaging and laser therapies improving early-stage disease treatment outcomes

Technological improvements in retinal imaging and therapeutic laser procedures are strengthening clinical capabilities across screening, diagnosis, and treatment, supporting the diabetic retinopathy market growth. High-resolution imaging allows clinicians to identify subtle retinal changes, assess disease progression, and monitor treatment response with greater precision, while laser-based therapies remain important for managing retinal complications and reducing the risk of further visual deterioration. Greater integration of imaging with ophthalmic workflows also enables more consistent disease assessment and supports timely treatment decisions for patients identified before significant vision loss occurs.

AI-enabled retinal screening adoption enhancing early detection in primary care settings

The increasing use of artificial intelligence for retinal image analysis is expanding access to diabetic eye screening and will propel the diabetic retinopathy market growth by enabling earlier identification of patients requiring specialist evaluation. AI-assisted systems can analyze retinal images within primary care and community-based workflows, helping healthcare providers recognize abnormalities without requiring every screening encounter to be conducted directly by an ophthalmologist. This approach can improve referral pathways, support screening in areas with limited specialist availability, and facilitate more systematic monitoring of patients at elevated risk of retinal complications.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising diabetes prevalence and aging population increasing risk of vision impairment cases	2.00%	High	North America, Asia Pacific	High	Near Term
Advanced diagnostic imaging and laser therapies improving early-stage disease treatment outcomes	1.70%	Moderate	North America, Europe	High	Mid Term
AI-enabled retinal screening adoption enhancing early detection in primary care settings	1.60%	Moderate	Asia Pacific, North America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest share of the diabetic retinopathy market in 2026, supported by well-developed healthcare infrastructure, strong access to advanced ophthalmic diagnostic and treatment technologies, and greater awareness of diabetes-related eye complications. The region benefits from established screening practices that encourage earlier identification of retinal abnormalities, while the increasing adoption of digital imaging, retinal monitoring, and minimally invasive treatment approaches strengthens clinical capabilities. Broad access to specialized eye-care services and continued investment in healthcare technology also supports demand for diagnostic and therapeutic solutions, helping North America maintain its leading market position.

Asia Pacific is expected to represent the fastest-growing regional market, driven by the expanding diabetic population, improving healthcare infrastructure, and rising awareness of the importance of routine eye screening. Increasing healthcare expenditure and the gradual expansion of specialized ophthalmology services are improving access to diagnosis and treatment, particularly across developing healthcare systems. Greater adoption of advanced retinal imaging and teleophthalmology solutions is also helping address gaps in specialist availability, while government and healthcare initiatives focused on diabetes management are creating a stronger foundation for sustained market expansion.

Key Country Insights

United States

AI Screening Adoption

The U.S. is expanding diabetic retinopathy screening through AI-assisted diagnostics and broader integration with diabetes management programs. Healthcare providers are prioritizing earlier detection and timely referrals to reduce preventable vision complications.

Japan

Preventive Vision Management

Japan is emphasizing routine diabetic retinopathy screening to address vision risks associated with an aging diabetic population. Healthcare providers are incorporating advanced retinal imaging and regular follow-up programs to support early clinical intervention.

South Korea

Digital Screening Networks

South Korea is expanding digital eye screening capabilities for diabetic retinopathy through advanced imaging systems and connected healthcare services. Hospitals and specialty clinics are focusing on efficient diagnosis and timely treatment planning for high-risk patients.

Germany

Integrated Eye Care

Germany is strengthening diabetic retinopathy management by improving coordination between ophthalmologists, diabetes specialists, and primary care providers. Screening initiatives and digital imaging technologies support earlier diagnosis and more consistent patient monitoring.

France

Early Detection Programs

France continues promoting structured diabetic retinopathy screening within chronic disease management initiatives. Healthcare professionals are enhancing access to retinal examinations and coordinated follow-up care to improve long-term visual health outcomes.

Italy

Ophthalmic Care Coordination

Italy is strengthening diabetic retinopathy management through closer collaboration between diabetes clinics and ophthalmology services. Healthcare providers are improving screening participation and diagnostic pathways to enable earlier treatment for patients at risk of vision loss.

Segment Leadership and Growth Trends

 

Type Segment Analysis: Non-proliferative Diabetic Retinopathy (Largest Segment) vs Proliferative Diabetic Retinopathy (Fastest-Growing Segment)

The non-proliferative diabetic retinopathy segment accounted for the largest share of the diabetic retinopathy market in 2026, representing 67.39% of the market. Its leading position is associated with the high prevalence of early-stage retinal changes among people living with diabetes and the importance of routine screening for identifying disease progression. Increased awareness of diabetes-related eye complications and wider use of retinal examinations are supporting earlier detection and management. Greater emphasis on preventing vision deterioration through timely intervention continues to reinforce demand related to non-proliferative disease.

Proliferative diabetic retinopathy is projected to grow at the fastest rate as advances in screening and disease monitoring improve identification of patients progressing to more advanced retinal complications. This stage can require intensive management to reduce the risk of severe vision loss, increasing demand for specialized ophthalmic interventions. Growing attention to early referral, improved disease surveillance, and access to advanced treatment options is expected to support the segment's expansion.

Management Segment Analysis: Anti-VEGF (Largest Segment) vs Laser Surgery (Fastest-Growing Segment)

Anti-VEGF therapy led the diabetic retinopathy market in 2026, supported by its important role in managing retinal complications associated with abnormal blood-vessel growth and vascular leakage. These therapies are widely incorporated into ophthalmic treatment strategies because they can target key biological mechanisms contributing to vision-threatening retinal damage. Increasing clinical focus on preserving vision and managing diabetic eye complications through pharmacological intervention supports the strong position of the anti-VEGF segment.

Laser surgery is expected to experience the fastest growth as ophthalmic care continues to emphasize effective intervention for retinal damage and disease progression. Laser-based procedures can help manage abnormal retinal blood vessels and reduce complications associated with advanced diabetic eye disease. Continued improvements in ophthalmic treatment techniques and greater access to specialized retinal care are expected to support increasing utilization of laser surgery.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Proliferative Diabetic Retinopathy, Non-proliferative Diabetic Retinopathy	Non-proliferative Diabetic Retinopathy	Proliferative Diabetic Retinopathy
Management	Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy	Anti-VEGF	Laser Surgery

Competitive Landscape and Market Positioning

Key companies in the diabetic retinopathy market:

1. Bayer AG (Germany)

2. AbbVie Inc. (United States)

3. Novartis AG (Switzerland)

4. Genentech Inc. (United States)

5. Alimera Sciences Inc. (United States)

6. Kowa Company Ltd. (Japan)

7. Oxurion NV (Belgium)

8. Sirnaomics Ltd. (United States)

9. Regeneron Pharmaceuticals Inc. (United States)

10. F. Hoffmann-La Roche Ltd. (Switzerland)

The diabetic retinopathy market is advancing through improved diagnostic precision and enhanced treatment intervention strategies. Research-driven innovation is enabling earlier detection and more targeted therapeutic approaches. Collaborative development efforts are strengthening integration between diagnostic tools and treatment systems for better clinical outcomes.

Industry Development/News

Company Name	Date	Key Development
Bayer AG	Apr-25	Entered a definitive agreement to acquire Perfuse Therapeutics for up to $2.45 billion. This acquisition significantly bolsters Bayer’s ophthalmology pipeline by integrating therapies focused on ischemia-related ocular diseases, marking a strategic expansion of the firm’s competitive position in retinal and vision-care therapeutics.
Sandoz	Mar-25	Completed the acquisition of a Lucentis biosimilar business from Coherus BioSciences. This transaction represents a key strategic move for Sandoz to strengthen its ophthalmology portfolio and increase its market share in the competitive landscape of retinal disease therapeutics following its transition to an independent company.
Celltrion	Mar-25	Secured U.S. FDA approval for its aflibercept biosimilar, Eydenzelt. This milestone broadens the availability of cost-effective treatment alternatives in retinal disease management and is expected to intensify price and service competition within the anti-VEGF market, directly impacting the clinical standard of care for diabetic retinopathy.
Optain Health	Mar-25	Acquired EyePACS to integrate advanced retinal screening capabilities into primary care settings. This strategic consolidation of diagnostic platforms facilitates the wider deployment of retinal imaging technologies, improving the infrastructure for the early detection of diabetic retinopathy and other systemic diseases in non-specialized clinical environments.
Exonate	Mar-25	Advanced the clinical development of EXN407 by initiating a Phase IIb CLEAR-DE trial for non-proliferative diabetic retinopathy. The study is a critical step in evaluating the efficacy of a novel topical treatment approach, which could represent a significant therapeutic innovation in managing the progression of diabetic eye disease.
Eyenuk	Jun-23	Secured FDA clearance to integrate the EyeArt AI system with the Topcon NW400 retinal camera. As the first AI system cleared to operate across multiple manufacturer platforms, this development enhances the scalability and adoption of automated screening for both mild and vision-threatening diabetic retinopathy.
AEYE Health	Apr-24	Received FDA approval for the AEYE-DS system, a fully autonomous AI-driven diagnostic tool. By utilizing handheld retinal cameras for autonomous detection, the system streamlines the screening workflow, representing a significant technological advancement in the efficiency and accessibility of diabetic retinopathy diagnostic services.
Valo Health	Mar-25	Terminated the development of its ROCK 1/2 inhibitor candidate following unsuccessful results in a Phase II clinical trial. The failure to demonstrate efficacy in reducing disease severity marks a strategic pivot in the company's R&D focus and impacts the current pipeline of emerging pharmacological interventions for the condition.
AEYE Health & Optomed Oyj	May-24	Formalized a commercial collaboration resulting in FDA clearance for the Optomed Aurora handheld fundus camera. This integration of AI-assisted imaging technology into portable hardware significantly lowers barriers to entry for rapid, high-quality retinal screening, fundamentally shifting the diagnostic delivery model in the diabetic retinopathy market.
Regeneron Pharmaceuticals	Mar-25	Reported positive pivotal trial results for Eylea HD in retinal vein occlusion and initiated regulatory filing plans. This expansion of the high-dose aflibercept franchise strengthens the company's competitive standing in retinal care and reinforces its dominant position in treatment segments relevant to diabetic retinopathy.